Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel
TSE:MDNA

Medicenna Therapeutics Q2 2026 Earnings Report

Medicenna Therapeutics logo
C$0.45 +0.03 (+7.14%)
As of 02:58 PM Eastern
ProfileEarnings History

Medicenna Therapeutics EPS Results

Actual EPS
-C$0.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Medicenna Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Medicenna Therapeutics Announcement Details

Quarter
Q2 2026
Date
11/13/2025
Time
After Market Closes
Conference Call Date
Thursday, November 13, 2025
Conference Call Time
7:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Medicenna Therapeutics' Q2 2026 Press ReleasePress Release

Medicenna Therapeutics Earnings Headlines

Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
June 3 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/03/3305914/0/en/medicenna-s-mdna11-potential-in-earlier-line-melanoma-setting-highlighted-in-presentation-of-the-neo-cyt-trial-at-asco-2026.html
Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs
May 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/28/3302952/0/en/medicenna-announces-closing-of-public-offering-of-units-raising-cdn-4-44-million-to-support-lead-programs.html
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel
June 3 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Medicenna Therapeutics Corp.
May 25, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/mdna/financials?countrycode=ca
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
May 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/22/3300037/0/en/medicenna-announces-the-filing-of-its-prospectus-supplement-and-investment-term-sheet.html
Medicenna Announces the Finalization of the Terms of its Public Offering of Securities
May 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/19/3297332/0/en/medicenna-announces-the-finalization-of-the-terms-of-its-public-offering-of-securities.html
See More Medicenna Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medicenna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicenna Therapeutics and other key companies, straight to your email.

About Medicenna Therapeutics

Medicenna Therapeutics (TSE:MDNA) Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.

View Medicenna Therapeutics Profile
Earnings Tools